Clinical data | |
---|---|
Trade names | Naropin, Rocaine |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Parenteral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 87%–98% (epidural) |
Metabolism | Liver (CYP1A2-mediated) |
Elimination half-life | 1.6–6 hours (varies with administration route) |
Excretion | Kidney 86% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.128.244 |
Chemical and physical data | |
Formula | C17H26N2O |
Molar mass | 274.408 g·mol−1 |
3D model (JSmol) | |
Melting point | 144 to 146 °C (291 to 295 °F) |
| |
| |
(verify) |
Ropivacaine (rINN) /roʊˈpɪvəkeɪn/ is a local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer. Ropivacaine hydrochloride is commonly marketed by AstraZeneca under the brand name Naropin.